Patent ID: 9629559
Date: 2017-04-25
CPC Classifications: A61B,G16H

Claim:
1. A system for determining homeostatic risk in a patient, in order to screen metabolic diseases and/or their complications and/or their treatment management, the system comprising: a plurality of sensors coupled with the patient, wherein the plurality of sensors includes: i) a galvanic skin response sensor that generates positive, above-ground voltage and negative, below-ground voltage and measures galvanic skin response, ii) a bioimpedance sensor for measuring bioimpedance in tetra-polar mode and a frequency of 50 KHz, iii) a pulse oximeter sensor set to a frequency of 60 Hz for measuring a photoplethysmogram (PTG) waveform with a frequency of 1 Hz, and iv) a blood pressure sensor for measuring blood pressure; a processor communicatively coupled with the plurality of sensors, the processor configured for: a) executing a spectral analysis on the PTG using Fast Fourier Transform computing a Discrete Fourier Transform (DFT) of a sequence with a reference heart rate having frequency values fixed at 1 Hertz at a heart rate of 60 bpm, thereby generating three constituent frequencies: PTG high frequency (PTGHF), PTG low frequency (PTGLF) and PTG very low frequency (PTGVLF) based on the PTG; b) calculating PTG Total Power (PTGTP) as equal to PTGHF+PTGLF+PTGVLF; c) calculating PTG index (PTGi) of the spectral analysis as equal to amplitude of PTGHF+amplitude of PTGLF+amplitude of PTGVLF; d) calculating PTG VLF index (PTGVLFi) of the spectral analysis as equal to PTGVLF divided by a value derived from the galvanic skin response; e) calculating PTG ratio (PTGr) of the spectral analysis as equal to PTGVLF divided by PTGi; f) calculating a heart rate variability based on the PTG and calculating a stress index based on the heart rate variability; g) calculating −da as equal to an amplitude of a fourth point of a second derivative of the PTG divided by an amplitude of a first point of the second derivative of the PTG, reflection index (RI), which is a measure of artery stiffness, left ventricular ejection time (LVET) as equal to a time between a global maxima of the PTG, and a dicrotic notch of the PTG, and pre-ejection period (PEP) as equal to a time between a global minima of the PTG and a global maxima of a first derivative of the PTG; h) calculating a first score based on PTGTP, stress index, PTGLF, PTGHF, RI, −da, PEP, LVET, PTGi, PTGVLFi, and PTGr; i) calculating electro skin response nitric oxide (ESRNO), which is a measure of an average of maximum conductance and conductance at 15 seconds after the maximum conductance at a particular electrode, Peak C, which is a maximum conductance reading, and electro skin response latency (ESRL), which is a measure of an amount of time between change of polarity of the galvanic skin response sensor and Peak C, based on the galvanic skin response; j) calculating a second score based on the ESRNO, ESRL and the Peak C; k) calculating body mass index (BMI) fat mass based on the bioimpedance; l) calculating a third score based on the BMI and fat mass; m) calculating systolic pressure, diastolic pressure and ankle-brachial index (ABI) based on the blood pressure; n) calculating a fourth score based on the systolic pressure, diastolic pressure and ABI; o) calculating a homeostatic risk score based on the first, second, third and fourth scores that were calculated, wherein the homeostatic risk score corresponds to the homeostatic risk of the patient; and a display for displaying the homeostatic risk score.